Company intelligence / Profile preview
Phytomedics
Jamesburg, New Jersey, United Statesphytomedics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Phytomedics has advanced a lead botanical drug candidate, PMI‑001, for rheumatoid arthritis into Phase III development following successful Phase II results. The company also develops additional clinical candidates targeting metabolic and age-related diseases. Its proprietary platform enables the discovery and manufacture of novel multi-component pharmaceuticals using plant biotechnology and rhizosecretion technology for cost-effective recombinant protein production.
- Therapeutic areas
- ImmunologyEndocrinologyOther
- Modalities
- Small moleculeRecombinant proteinBotanical drug (multi-component botanical therapeutics)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Phytomedics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phytomedics.